Context Therapeutics Inc., a clinical-stage biopharmaceutical company, has appointed Dr. Karen Chagin as Chief Medical Officer, effective June 9, 2025. Dr. Chagin, who has extensive experience in T cell therapies for solid tumors, previously held a senior position at Adaptimmune Therapeutics. She succeeds Dr. Karen Smith, who will remain on the company's Board of Directors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9459745-en) on May 29, 2025, and is solely responsible for the information contained therein.